SCHEMBL1680400

SCHEMBL1680400

N#Cc1ccc(OCc2cccs2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.54
TRPM8 Q7Z2W7 1/20 0.53
HPGD P15428 1/20 0.48
ALDH1A1 P00352 2/20 0.43
F9 P00740 1/20 0.43
F10 P00742 1/20 0.43
NSD2 O96028 1/20 0.43
NSD3 Q9BZ95 1/20 0.43
KCNA5 P22460 1/20 0.42
SCN9A Q15858 2/20 0.42
PDK2 Q15119 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
SLC6A2 P23975 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
HTR2B P41595 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6616525 0.80 TDP1 (0.51) TRPM8HPGDF9F10PDK2
SCHEMBL10661599 0.79 CYP1A2 (0.54) MAOBTRPM8HPGDALDH1A1F9
SCHEMBL7890449 0.79 MAOB (0.52) MAOBHPGDF9F10PDK2
SCHEMBL20319189 0.79 HPGD (0.50) TRPM8HPGDF9F10PDK2
SCHEMBL920854 0.79 HPGD (0.47) TRPM8HPGDALDH1A1F9F10
SCHEMBL8306329 0.79 SMN1; SMN2 (0.54) MAOBTRPM8HPGDF9F10
SCHEMBL22305088 0.77 F9 (0.49) HPGDALDH1A1F9F10PDK2
SCHEMBL1680389 0.76 MAOB (0.54) MAOBHPGDF9F10
SCHEMBL28677901 0.75 LOXL2 (0.46) TRPM8ALDH1A1NSD2NSD3PKM
SCHEMBL1299736 0.75 HPGD (0.60) HPGDALDH1A1F9F10PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 MAOB 1175/4885TRPM8 1380/4885HPGD 2538/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD MAOB 2220/4885TRPM8 1930/4885HPGD 1490/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 MAOB 1205/4885TRPM8 1573/4885HPGD 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.